Few years ago, liraglutide, a GLP-1 receptor agonist, was approved by the US Food and Drug Administration as an obesity treatment option and shown in clinical trials to be effective in reducing and sustaining body weight loss (3.0 mg / day) [11]. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.